Quebec City, Quebec, June 22, 2016 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) today announced receipt of Health Canada approval to sell the OptoWire II in Canada. The OptoWire II is an optical guidewire developed to measure Fractional Flow Reserve (“FFR“). FFR measurement is used for the diagnostic of the severity of coronary stenosis to guide treatment in patients with coronary artery disease.
“Opsens is pleased to offer its improved optical guidewire to Canadian cardiologists, where the Company already has multiple regular customers,” said Louis Laflamme, President and CEO of Opsens. “The OptoWire II is now authorized for sale in all our targeted markets: U.S., Europe, Japan and Canada, which together represent 85% of the FFR worldwide market,” he concluded.
In order to provide cardiologists with the most effective products to measure FFR, Opsens has developed the OptoWire II, an improved version of the original OptoWire, which has a hydrophilic coating that further enhances the performances of the guidewire, such as when used in highly calcified and tortuous vessels.
The interventional cardiology community has provided a warm and enthusiastic welcome to Opsens’ FFR products, prompting the Company to put in place the resources to grow strongly. Opsens has assembled a team with experience and expertise in the sale of FFR products. In addition, Opsens has completed its move to a new state-of-the-art facility, which will allow the Company to increase production and meet the growing demand for its FFR products.
Opsens aims to become a key player in the guidewire FFR market with the OptoWire, a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire that provides optimal performance to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources, the FFR market represented more than US$300 million in sales in 2014 and is expected to reach US$1 billion in the medium-term.
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Thierry Dumas, CPA, CA, Chief Financial Officer, 418.781.0333
Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333